• Sisram Medical flagged a swing to a net loss attributable to owners of US$0.9 million–US$1.4 million for H1 2026 from a US$6.4 million profit.
• Revenue expected at no less than US$171 million, up from US$165.5 million a year earlier.
• Loss outlook driven by weaker North America sales amid tough market conditions, continued investment in the injectables business in mainland China.
• Revenue growth cited across APAC, Europe, Middle East and Africa, supported by rising contributions from the Injectables segment.
• Interim results for the six months ended June 30, 2026 due by end-August 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sisram Medical Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260803-12267342), on August 03, 2026, and is solely responsible for the information contained therein.